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Abstract
The Major Histocompatibility Complex (MHC) plays an important role in the human immune system. The MHC is involved in
the antigen presentation system assisting T cells to identify foreign or pathogenic proteins. However, an MHC molecule
binding a self-peptide may incorrectly trigger an immune response and cause an autoimmune disease, such as multiple
sclerosis. Understanding the molecular mechanism of this process will greatly assist in determining the aetiology of various
diseases and in the design of effective drugs. In the present study, we have used the Fresno semi-empirical scoring function
and modify the approach to the prediction of peptide-MHC binding by using open-source and public domain software. We
apply the method to HLA class II alleles DR15, DR1, and DR4, and the HLA class I allele HLA A2. Our analysis shows that using
a large set of binding data and multiple crystal structures improves the predictive capability of the method. The
performance of the method is also shown to be correlated to the structural similarity of the crystal structures used. We have
exposed some of the obstacles faced by structure-based prediction methods and proposed possible solutions to those
obstacles. It is envisaged that these obstacles need to be addressed before the performance of structure-based methods
can be on par with the sequence-based methods.
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Introduction
Multiple sclerosis (MS) is a neurological disease characterised by
inflammation and demyelination in the central nervous system.
MS is regarded as an autoimmune disease by many researchers
[1–5], however, the pathogenesis of the disease is not well
understood. Genetic linkage analyses of MS patients have
identified the DRB1*1501 and DQB1*0602 alleles of the Major
Histocompatibility Complex (MHC) molecule as definite genetic
risk factors [2,5]. This has been confirmed in more recent genome
wide association studies [6]. The MHC molecule is involved in the
antigen presentation system and assists the T cells to identify
pathogenic proteins. While the overall antigen presentation
mechanism is reasonably well understood, the specificity and
sensitivity of peptide binding to MHC molecules, and the binding
of T-cells to the resultant complex, required to elicit an immune
response, is not well defined. Deeper knowledge of the peptide
binding process may help to isolate the cause of the disease and
detect peptides with therapeutic potential.
Currently, there are three schools of MHC-peptide binding
prediction methods based on the information and approach used
in the prediction: sequence-motif (PSSM-) based, artificial
intelligence- (AI-) based, and structure-based. The first two schools
examine the patterns exhibited by the sequences of binding
peptides, whereas structure-based methods study the relationship
between the binding affinities and the structures of MHC-peptide
complexes.
Early work on peptides that bind to MHC molecules observed
patterns in the peptide sequences. Systemic analyses of the effects
of amino acids on the peptide binding affinities provide the basis
for position-specific scoring matrices to predict binding affinity [7–
10]. More recently, many studies introduced artificial intelligence
algorithms in the attempt to understand the subtle underlying
patterns [11–14]. Due to the type of input, PSSM- and AI-based
methods are sometimes generalised as sequence-based prediction
methods [14].
In addition to sequence information, structure-based methods
also incorporate additional structural information from experi-
mental crystal structures of MHC-peptide complexes [15–21].
Usually the atomic coordinates of the MHC molecule are
extracted from an experimental crystal structure as the frame
template, and the atomic coordinates of the peptide from the same
structure are used as the template for fitting new peptides. Once a
structure fitted with a new peptide is constructed, the structure
may be subjected to energy minimisation. Using the new structure,
the distance between two atoms and the physiochemical properties
of the atoms are used to determine if the interaction is beneficial or
not to the binding.
Much effort has been put into developing sequence-based
methods, which have shown considerable performance [8,11,
14,22]. On the other hand, the availability of experimentally
determined structures allows structure-based methods to study the
precise relationship between the structure and peptide binding
specificity. The inclusion of structural information may reveal
properties affecting the binding not obvious on the sequence level.
Furthermore, the recent increase in the number of experimentally
determined structures for MHC-peptide complexes is expected to
provide further data to improve the performance of structure-
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computational methods for predicting peptide binding to the
MHC, particularly structure-based methods, has been written by
Liao and Arthur [23].
Despite considerable research into the development of compu-
tational techniques for determining peptide binding to the MHC
and successful predictions for some alleles, the performance of
various binding prediction algorithms for MHC class II alleles,
including DRB1*1501, is still relatively poor. Previously, Rognan
et al. [24] had some success in predicting the binding affinity of
peptides for the HLA A*0201 allele using a structure-based
method. In the present study, we adopt the Fresno semi-empirical
scoring function developed by Rognan et al. to study peptide
binding to MHC class I and II alleles in order to improve the
computational prediction of peptide binding to DRB1*1501.
Results
Validation of the prediction method
In this study, we adapted the semi-empirical method for
predicting peptide binding affinity for MHC class I molecules
originally proposed by Rognan et al. [24]. The public domain
software packages MolProbity [25] and SCWRL 4 [26] were used
instead of SYBYL BIOPOLYMER to add hydrogen atoms to the
crystal structures and predict peptide side chain atomic positions.
The modelling algorithm was implemented in PERL and R was
used to perform the partial-least-square regression analysis with
leave-one-out cross-validation.
The open source adaptation of the protocol was tested using the
original five HLA-A0201 (A2) structures (the Madden structures)
used by Rognan et al. Table 1 compares the experimental free
energy of binding with the theoretical values of Rognan et al. and
our analysis. In each case, our prediction more accurately
estimates the experimental free energy of binding. The cross-
validation correlation score, q
2, was excellent at 0.971 and the
standard error of prediction, Spress, was appropriately low at 0.727.
In comparison, Rognan et al. achieved a q
2 value of 0.895 and a
Spress value of 3.448. Thus, we established that our approach, using
open source equivalents and our own PERL implementation of
the Fresno scoring function, performs better than the original
implementation.
Validation of our open source adaption of the method is crucial
to ensure the integrity of our PERL implementation of the
technique and the alternate use of open source applications. By
repeating the analysis of Rognan et al., we were able to show that
our open source adaptation of the method reproduces the results
of the original analysis, thus validating our adaptation. In fact, our
approach generates slightly more accurate predictions than the
original method.
Prediction of peptide binding to HLA-DR15
Having validated the prediction method, we applied the
procedure to the prediction of the free energy of peptide binding
in HLA-DRB1*1501 (DR15). The HLA-DR15 allele of the MHC
is a major genetic risk factor for MS. Our aim here was to use the
method developed and validated above to predict peptide binding
in this allele as a step to understanding the role this allele plays in
the pathogenesis of MS.
There are only two experimentally determined structures for
HLA-DR15: 1YMM and 1BX2. 1YMM was chosen as a
reference structure as it was the most recently published crystal
structure. The AntiJen database contains 188 entries of peptides
with peptide binding data for HLA-DR15. Of these, only twenty
peptides were fourteen amino acids in length as required to match
the length of the peptide in the 1YMM reference structure. These
peptides are shown in Table 2.
Each peptide was modelled in the binding groove of the MHC
molecule and the resulting structure used to determine the terms of
Fresno scoring function (equation 2). The resulting equations for
all twenty peptides were then subjected to the statistical analysis to
determine the regression coefficients. These regression coefficients
are then used to predict the theoretical binding free energy for
each peptide for comparison with the experimental data. After the
cross-validation analysis, the q
2 value for the analysis was 0.243
and Spress was 6.429 confirming the prediction method was unable
Table 1. Comparison of the free energies for five HLA-A*0201
structures.





TLTSCNTSV 1HHG 237.32 236.85 (20.47) 237.19 (20.13)
FLPSDFFPSV 1HHH 248.45 248.56 (+0.11) 248.41 (20.04)
GILGFVFTL 1HHI 246.94 247.03 (+0.09) 247.01 (+0.07)
ILKEPVHGV 1HHJ 237.60 238.96 (+1.36) 237.74 (+0.14)
LLFGYPVYV 1HHK 245.48 245.57 (20.09) 245.43 (20.05)
aExperimental values from the original publications.
bPredictions made by Rognan et al. in the original Fresno implementation; the
deviations from the experimental values are included in parentheses.
cOur predictions; the deviations from the experimental values are included in
parentheses.
doi:10.1371/journal.pone.0025055.t001
Table 2. All twenty 14-mer peptides with experimental
binding data in regard to HLA-DR15 extracted from AntiJen.
Peptide IC50 (nmol) Temp (6C)
ADTISSYFVGKMYF [40] 160 37
DENPVVHFFKNIVT [41] 4.6 37
DTISSYFVGKMYFN [41] 780 37
ENPVVHFFKNIVTA [41] 12 37
FNLIDTKCYKLEHP [41] 35000 37
GKMYFNLIDTKCYK [41] 33000 37
HFFKNIVTPRTPPY [41] 405 37
ISSYFVGKMYFNLI [41] 1600 37
KMYFNLIDTKCYKL [41] 68000 37
KNSADTISSYFVGK [41] 210 37
MYFNLIDTKCYKLE [41] 6500 37
NLIDTKCYKLEHPV [41] 40000 37
NPVVHFFKNIVTPR [41] 6.8 37
NSADTISSYFVGKM [41] 330 37
SADTISSYFVGKMY [41] 230 37
SSYFVGKMYFNLID [41] 1600 37
SYFVGKMYFNLIDT [41] 400 37
TISSYFVGKMYFNL [41] 190 37
YFNLIDTKCYKLEH [41] 15000 37
YFVGKMYFNLIDTK [41] 33000 37
doi:10.1371/journal.pone.0025055.t002
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DR15.
To confirm this result was not due to an anomaly with the
1YMM structure, we also repeated the analysis with the 1BX2
structure. Similar results were obtained (data not shown).
Thus, the success of the scoring function in reproducing, and
slightly improving, the results of Rognan et al. with the class I
A*0201 allele, was not seen when working with the class II
DRB1*1501 allele. This prompted us to a detailed examination of
the Rognan et al. scoring function and its applications to assess the
efficacy of the method in different circumstances.
Effect of data quantity on prediction accuracy
One possible explanation for the failure to adequately predict
binding free energies in HLA-DR15 compared to the success in
predictions with HLA-A2 may relate to class II MHC molecules
requiring a larger set of binding data to better predict peptide
binding. However, as noted above, only twenty peptides of
appropriate size are contained in the AntiJen database for HLA-
DR2.
In order to test this hypothesis, we considered HLA-
DRB1*0101 (DR1) and HLA-DRB1*0401 (DR4): the two most
studied class II alleles. Multiple PDB entries can be found for both
HLA-DR1 and HLA-DR4 alleles. The most recently published
structures with the best resolution were used as reference
structures (1FTY and 1J8H). Both these alleles have more peptides
with experimental binding data in the AntiJen database than
HLA-DR15 with 74 peptides from 11 studies meeting the selection
criteria for HLA-DR1 and 58 usable peptides from the same study
for HLA-DR4.
The calculated q
2 and Spress values for HLA-DR1 were 0.275
and 7.795 respectively. The calculated q
2 and Spress values for
HLA-DR4 were 0.283 and 6.390. Thus, using larger peptide
binding data reference sets results in a modest improvement in
both the cross-validation correlation score and the standard error
of prediction to DR-15. However, the former remains low, and the
latter high, indicating that the predictive capacity of the method
remains poor. This suggests that while the quantity of peptide
binding data does have an impact on the predictive ability of the
scoring function, it is not the primary factor.
Effect of MHC class on prediction accuracy
Another possible factor affecting the prediction may be the class
of MHC molecule used as the reference structure. The original
method of Rognan et al. was developed and tested on MHC class I,
and allele A*0201 in particular. It is possible that the more open
topology of the MHC class II structure means the approach is not
suitable, at least in its current form, for class II molecules. To
explore this possibility, we attempted to duplicate our experiments
above, but with class I molecules, and the A*0201 allele in
particular.
As a reference structure, we chose 2GTW for the HLA-A2 allele
[27]. This structure is not one of the five Madden structures, has a
high resolution, and was published recently. A list of 174 peptides
from 22 studies was extracted from the AntiJen database. Thus,
our selection replicates the selection we made previously for a class
II allele.
The calculated q
2 and Spress values using the structure 2GTW
were 0.01974 and 6.037. Thus, even using a class I structure, with
a large set of peptide binding data, the technique does not achieve
good predictive capability. To confirm this, we repeated the
experiment using one of the five Madden structures as a reference.
Since the peptide in the structure 1HHH is longer (decamer) than
the other structures (nonamers), the 1HHH data was incorporated
in two ways. The peptide of 1HHH was either truncated at the N-
terminal or the C-terminal of the peptide in order to fit into the
other structures with nonamers, or the peptide was excluded from
the analysis completely. The MHC structure of 1HHH structure
was not used at all, since peptides from the other structures will not
fit. The procedure was repeated for each of the four structures
(1HHG, 1HHI, 1HHJ, and 1HHK).
When the peptide from 1HHH was not used (i.e. only four
peptides were used as input data), 1HHG, 1HHI, and 1HHJ
returned low q
2 values suggesting no predictive capability for the
technique. The q
2 and Spress values for 1HHK, however, were
significantly better at 0.7897 and 1.75, although still not nearly as
good as the values seen in the validation study. When the peptide
from 1HHH was used, none of the reference structures was able to
return a good result.
The favourable result for 1HHK presented a possible reason for
the performance of validation study. 1HHK was therefore used as
the reference structure in a further analysis under the same
conditions used for 2GTW. However, this analysis gave q
2 and
Spress values of 0.002 and 6.083.
Predictive capability is dependent on quantity of
structural data
The previous experiments consistently showed poor predictive
capability for the approach, despite the remarkable success of the
approach in the validation study. A final point of difference
between the experiments is that the validation study uses five
reference structures i.e., in calculating the terms and thence the
regression coefficients, the atomic distances used are those of the
peptide in its native crystal structure. In contrast, the other studies
use peptides modeled in a single reference crystal structure.
Since calculation of the free energy of binding is based on the
reference structure, if the predicted structure is different from how
the peptide binds the MHC molecule natively, it may damage the
predictive performance of the method. Thus, using a large set of
reference structures simultaneously may provide more structural
information and thus lead to better predictions.
To test the hypothesis, we searched PDB for HLA-A2 structures
with one of the 174 peptides previously collected from AntiJen
database, and found 17 structures, including 1HHJ (Table 3).
Fourteen of them share one of three common peptides
(ILKEPVHGV, NLVPMVATV, and SLLMWITQC) with other
structures. Thus, we used various combinations of 6 structures,
consisting of the 3 unique structures and a combination of
three structures chosen from the 14 structures sharing the three
common peptides, such that only one structure with each peptide
was used.
The q
2 and Spress values varied between 0.998 to complete
randomness. However, most combinations (57 combinations)
showed improvement over the best of the previous analyses using
a single reference structure (q
2 value of 0.283) and nearly half of
the combinations (37 combinations) achieved a q
2 value greater
than 0.5 (Fig. 1). This supports our hypothesis that using multiple
reference structures will boost the prediction performance.
Yet, the effect is not definitive. While most sets of reference
structures generate better results than a single reference structure,
the predictive capability still varies depending on the reference set
chosen, with many reference sets still showing less than adequate
predictive capability, despite improvements over single reference
structure methods.
To examine the potential impact of different structural
characteristics on the predictive performance, we explored the
correlation between q
2 and Spress values and various characteristics
of the structures (Table 4). The first of these was the average
Structure-Based Prediction of MHC-Peptide Binding
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The RMSD was calculated for all the combinations used in
the analysis using the atoms from the MHC molecule alone,
the peptide alone, and the whole structure. The RMSD scores
were calculated for all pairs of structures in the set of reference
structures and the results averaged to give a mean RMSD
score for the set The RMSD scores were compared to the
corresponding q
2 and Spress values using Spearman’s rank
correlation. Secondly, the q
2 and Spress values were also compared
to the average resolution of the structures using Spearman’s rank
correlation. A correlation coefficient of 1 (or 21) indicates perfect
correlation in the same (or opposite) direction. A value of 0
indicates no correlation.
The Spearman’s coefficient between the q
2 values and the
RMSD scores shows an intermediate correlation between average
RMSD score and q
2 value with a small average RMSD between
the structures giving rise to a high q
2 value, and thus better
predictive performance for the approach (Fig. 2). This is also the
case for the five Madden structures used in the original Fresno
study. The average RMSD score of the five Madden structures
was 0.57, which is better than all of the combinations used in the
analysis, giving rise to the high q
2 value and predictive
performance in the original study. The correlation between the
q
2 values and the RMSDMHC scores suggests that the correlation is
primarily attributed to the structure of the MHC molecule.
On the other hand, little correlation was seen between the
average resolution of the structures and the q
2 values. This suggests
that depth of resolution of the reference structures is not critical to
the predictive performance of the method.
Figure 1. Spread of q2 values for different combinations of reference structures. 37 out of 84 combinations of reference structures (44%)
achieved a q2 value greater than 0.5 and 57 (68%) achieved a q2 value greater than 0.283. which was the best predictive performance for analyses
using only one reference structure.
doi:10.1371/journal.pone.0025055.g001
Table 3. List of PDB entries and corresponding peptide
binding data.
Peptide Temperature (6C) IC50 (nmol) PDB
AAGIGILTV [42] 4 0.00008 2GUO
FLWGPRALV [42] 4 0.0000021 1QEW
ILKEPVHGV [43] 4 0.000008 1AKJ
ILKEPVHGV 4 0.000008 1HHJ
ILKEPVHGV 4 0.000008 1P7Q
ILKEPVHGV 4 0.000008 2X4U
IMDQVPFSV [44] 26 0.00000654 1TVH
NLVPMVATV [45] 4 0.0000125 2X4R
NLVPMVATV 4 0.0000125 3GSN
NLVPMVATV 4 0.0000125 3GSO
SLLMWITQC [46] 37 0.00002107 1S9W
SLLMWITQC 37 0.00002107 2BNR
SLLMWITQC 37 0.00002107 2F53
SLLMWITQC 37 0.00002107 2F54
SLLMWITQC 37 0.00002107 2P5E
SLLMWITQC 37 0.00002107 2P5W
SLLMWITQC 37 0.00002107 2PYE
doi:10.1371/journal.pone.0025055.t003
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In this series of experiments, we have shown that our imple-
mentation of the Fresno scoring function, using open source/free
software, reproduces the results of Rognan et al. and, in fact,
performs slightly better than the original implementation.
However, when the number of reference structures used is
reduced to one, the performance of the scoring function is greatly
diminished, even if a large set of peptide binding data is used. This
indicates that either MHC molecules assume quite different
positions whilst binding to different peptides or that the theoretical
approach used to predict peptide binding is quite sensitive to small
changes in MHC structure. If a MHC molecule binds to the
peptides more or less in the same way, the differences between
structures should be minimal, and the scoring function should still
be able to predict the binding affinity albeit with a less satisfying
performance. On the other hand, if the MHC molecule assume
different positions when binding to different peptides, multiple
structures will be required to effectively sample all possible
confirmations used as a basis for the semi-empirical model. Our
experiments demonstrate this to be the case. When only one of the
five structures used in the original Fresno study was used to analyse
the binding affinities of all the peptides, only one structure could
be used to achieve a good performance. Nonetheless, this
performance was still worse than using all five reference structures.
We also showed that even when one of the best structures for
HLA-A2 is used as the reference structure, the prediction
performance was still less than ideal, but when more reference
structures were employed the q
2 value can reach over 0.9. It is
therefore important to consider various binding confirmations
when constructing a free energy scoring function.
The best solution is to determine the structure for all binding
peptides used in both establishing the regression coefficients for the
scoring function as well as those whose binding free energy is to be
predicted. However, this need for structural information for each
peptide being considered makes it effectively impossible to use the
method in large scale computational studies, such as an exhaustive
scan of all possible peptides to predict potential epitopes for the
MHC molecule.
Two further approaches offer a potential solution to this
problem. The first is to obtain a large set of structures and use the
structure with the most similar peptide for the peptides that do not
have an experimentally determined structure. The other approach
is to derive a ‘‘consensus structure’’ by averaging all the available
structures. A consensus structure may sacrifice accuracy for some
peptides but will hopefully be able to fit most peptides within a
Figure 2. The comparison of q2 values and RMSD scores shows a general negative correlation. The point for the Madden structures is
the grey triangle located towards the top left of the figure.
doi:10.1371/journal.pone.0025055.g002
Table 4. Comparison between q
2 and Spress to the RMSD






Average resolution 20.103 0.105
Three RMSD scores were calculated based on the use of the structures.
RMSDMHC is the RMSD for the structure of the MHC molecule alone, RMSDpeptide
is the RMSD for the structure of peptide alone, and the RMSD for the whole
structure.
doi:10.1371/journal.pone.0025055.t004
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first may provide higher accuracy, however, the second approach
should be easier to implement.
Another obstacle for structure-based methods is the reduced set
of binding data. While sequence-based methods can simply
categorise peptides into binders or non-binders based on the
IC50 values, structure-based methods often rely on precise input,
which excludes implicit values, such as strong, intermediate, and
weak binding. Moreover, there is discrepancy in the binding data
for many peptides due to various experimental settings. Any slight
change in the input can produce a different result, and a large
inconsistency in the input can render the result useless. However,
discrepancies may be introduced in two areas: the detection
method and the choice of competing peptide in the competitive
assay. There are two detection methods based on the labelling tag,
either fluorescence or radioactive isotopes, used to label the target
peptide. While the two methods share the same principle, the
readings can vary greatly and a difference is observed between two
studies using different labelling method. In addition to the
detection methods, the choice of competing peptide is also an
important factor in determining the IC50 value. When two
competing assays are performed using the same detection method
and same experimental conditions but different competing
peptides, the relative binding affinity of the two competing
peptides will affect the resulting binding affinity of the target
peptide. If the first competing peptide is a better binder than the
second competing peptide, there will be a difference in the
resulting IC50 values. This may be the reason why two studies may
arrive at different IC50 values even though all the other
experimental conditions appear to be the same.
It is possible to include the implicit values if the scoring function
is classification-based, where input is classified into weak,
intermediate, or strong binders. Although this will inevitably
reduce the information used to deduce the scoring function and
reduce the accuracy of the scoring function, using a classification-
based approach will allow more input data. This may compensate
for the loss of specific binding information. Unfortunately, it is
impossible to resolve the discrepancy introduced by using different
competing peptides; prior knowledge will be required to be able to
choose one IC50 value over another.
In conclusion, the present study implemented the Fresno
scoring function using open source and free software. We have
also looked at some of the obstacles faced by researchers in the
attempt to develop free energy scoring functions. Currently,
sequence-based methods exploring binding motif or utilising
artificial intelligence are leading the race to accurately predict
peptide binding affinity. However, sequence-based methods do not
face the same obstacles as structure-based methods, as they do not
utilise structural information and tend to be classification based.
While structure-based methods are not so far behind, it is
foreseeable that these obstacles need to be addressed before the
performance of structure-based methods can be on par with the
sequence-based methods.
Materials and Methods
Preparation of MHC structures
A list of experimentally determined structures of the MHC-
peptide complex for alleles HLA-A*0201, HLA-DRB1*0101,
HLA-DRB1*0401, and HLA-DRB1*1501 (Table 5) were col-
lected from the Protein Data Bank [28]. For analyses where only
one structure was used the most recent structure with best
resolution was used. Structures, referred to as the Madden
structures hereafter, used by Rognan et al. in their study
(1HHG, 1HHH, 1HHI, 1HHJ, 1HHK) were also obtained from
the PDB [29].
Each crystal structure gives the positional information of the
atoms of the MHC molecule and a peptide of particular sequence
bound to the MHC molecule. In order to study the binding affinity
of other peptides, the structure of a new peptide, bound to the
same MHC molecule, is determined from the existing structure by
using the same positions for the backbone atoms and rebuilding
the side chains in the context of the MHC molecule. In the present
study, the side chain rebuilding was performed using SCWRL 4
[26]. SCWRL 4 preserves the positions of the backbone atoms for
the new peptide. It then attempts to predict the positions of the
side-chain atoms for the new peptide while considering steric
effects of the surrounding framework: in this case, the MHC
molecule. Once a structure with the new peptide was constructed,
hydrogen atoms were added using MolProbity 3.14 [30].
Preparation of peptide binding data
When the concentration of the binding peptide is sufficiently
low, the dissociation constant can be represented by the inhibitory
concentration (IC50): the concentration of inhibitor required to
halve the level of binding of the substrate to the enzyme in a
competitive assay. The free energy of binding can be calculated
from the experimental temperature in Kelvin (T), the IC50 value,
and the gas constant (R) according to equation 1.
Gexp~RT ln IC50 ðÞ ð 1Þ
A list of peptides with known binding affinity was extracted from
the AntiJen database for each allele [31–32]. The AntiJen
database contains experimental binding data for peptides known
to bind to MHC molecules. Only peptides with the same length as
the peptide in the reference crystal structure were used; typically,
these were nine amino acids long. Inconsistencies or implicit values
in the data set, such as multiple IC50 values for individual peptides
due to different experimental settings, were resolved by manual
reference to the original citations. If there is inexplicable
discrepancy, the peptides in question were excluded from the
analysis. The experimental data for the five structures used in
Rognan et al. were taken from their original publication [33].
Calculation of the Scoring Function Terms
The Fresno free energy scoring function was previously
described by Rognan et al. [24]. Briefly, there are five terms used
by the Fresno scoring function (equation 2). Each term attempts to






1HHG, 1HHH, 1HHI, 1HHJ,1HHK [29]
HLA-A*0201 1AKJ, 1B0R, 1OGA, 1P7Q, 1QEW, 1S9W, 1TVH, 2BNR,
2BNQ, 2F53, 2F54, 2GTW, 2GT9, 2GUO, 2P5E, 2P5W,
2PYE, 2X4U, 2X4R, 3GSN, 3GSO [27,47–57]
HLA-DRB1*0101 1FYT [58]
HLA-DRB1*0401 1J8H [59]
HLA-DRB1*1501 1YMM, 1BX2 [60–61]
The Madden structures were the five structures used in the original Fresno study.
doi:10.1371/journal.pone.0025055.t005
Structure-Based Prediction of MHC-Peptide Binding
PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e25055model the contribution to the binding energy made by a different
atomic interaction.
DGbinding~Kza HB ðÞ zb LIPO ðÞ zc BP ðÞ zd ROT ðÞ ze DESOLV ðÞ ð 2Þ
The first three terms describe the energies associated with
hydrogen bonds (HB), the interactions between lipophilic atoms
in the MHC molecule and the peptide (LIPO), and the
unfavourable interactions between polar and lipophilic atoms
(BP). The rotational term (ROT) estimates the loss of energy due
to the freezing of the rotatable bonds of the peptide upon binding.
Lastly, the desolvation term (DESOLV) considers the energies
required to solvate the MHC molecule, the peptide, and the
MHC-peptide complex. The equations and related details for
calculating each term are given in Rognan et al [24] and Eldrige
et al. [34].
Calculation of the Regression Coefficients
The HB, LIPO, ROT, and BP terms were calculated using an
adaptation of the Fresno scoring function developed in PERL. If
the reference PDB file contained a bound T-cell receptor, this part
of the file was removed prior to the analysis. The DESOLV term
for all peptides was estimated using the DelPhi program [35–36].
The parameters were similar to those used by Rognan et al. The
only difference being the atomic radii and the charges. Atomic
radii and charges used in this study were taken from PARSE [37].
The values of all terms and the experimental free energy are
used in a partial least square analysis using R and the pls package
[38–39]. Regression coefficients were derived for each term and
optimised for each dataset. The theoretical free energy was
predicted using these regression coefficients. The cross-validation
correlation score (q
2) and standard error of prediction (Spress) were
calculated from leave-one-out cross-validation using the built-in
functions (R2 and RMSEP) from the pls package. q
2 estimates the
accuracy of the model and Spress estimates the error rate of the
prediction. Thus a good prediction model should have q
2 close to 1
and a low Spress value.
Correlation Studies
The difference between protein structures was calculated in
terms of root mean square deviation (RMSD) scores. Structures
were superimposed and the RMSD values were calculated using
the Discovery Studio Visualizer 3.0 by Accelrys. Correlation
between the q
2 values and the RMSD scores were analysed using
Spearman’s rank correlation in R. Correlation between the q
2
values and the average resolution of structures, obtained from the
PDB structure files, was calculated similarly.
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